ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MESO / dividends
COAG (59) VIR (40) VCEL (58) ALVO (52) ⌘ Pro Terminal →

Mesoblast Limited (MESO) Dividend Safety Gauge & 10-Year DRIP Compounder

$14.54 -4.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.41

Mesoblast Limited (MESO) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.97B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MESO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MESO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Mesoblast Limited (NASDAQ: MESO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $14.54 (-4.09% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MESO ranks #252 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MESO compare to COAG and VIR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MESO carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COAG (Hemab Therapeutics Holdings Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $1.94B) and VIR (Vir Biotechnology Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.93B). Among the 5-stock peer group, VCEL leads on earnings multiple (133.0x) while VCEL leads on capital efficiency (3.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MESO?
▼

For Mesoblast Limited (MESO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #252 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $14.40 (-0.93%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (9)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.2% Base Target
$23 Bull$14 Base$11 Bear
📬 FREE MESO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MESO)Realized 20D OHLCV Swing Band: ±8.5%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY MESO SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 1.4% FCF Margin ($55.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)

Macro rate sensitivity & RSI-14 (57.2) create a -12 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$13.90-10.7% Next Q
Q2 (-2Q)
46
Grade D$12.41+6.2% Next Q
Q3 (-1Q)
48
Grade D$13.18+10.3% Next Q
Current
51
Grade D$14.54-1.3% Hist 90D α
Trajectory: D (43) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MESO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MESO currently carries a cautious 51/100 (D) rating due to Macro Regime Fit (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.87) and Max Pain ($15.27) forces dealer call-delta covering toward $22.57.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MESO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MESO Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MESO)

  • ✓Walkthrough of MESO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MESO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.13%▼ DESCENDING CHANNEL
2026-11-03O $15.67H $15.67L $14.54C $14.54VOL 376.0K
RES: $16.72SUP: $11.46SMA50: $14.87SMA200: $15.39
$19.88$17.72$15.55$13.38$11.22RES $16.72SUP $11.46$14.542026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MESO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MESO Butterfly Map → + Track MESO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MESO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MESO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MESO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MESO)

Health Care Rank #252 of 1015 ⚔️ COAG vs MESO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MESO vs. COAG, VIR, VCEL, ALVO)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Mesoblast Limited (MESO) ranks #252 by composite RQD confidence (51/100, grade D) and #255 by equity capitalization ($1.97B). Within this direct 5-issuer industry benchmark cohort, VCEL leads on earnings valuation at 133.0x trailing P/E, while VCEL leads on capital efficiency and profitability with 3.4% ROIC and 74.4% gross margin. COAG currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with MESO at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MESO ACTIVE
Mesoblast Limited
D 51/100 — — — -4.09% $1.97B Benchmark Subject
COAG
Hemab Therapeutics Holdings Inc.
C- 59/100 — — — -0.65% $1.94B /coag-vs-meso →
VIR
Vir Biotechnology Inc.
D- 40/100 — 96.0% -35.0% -2.65% $1.93B /vir-vs-meso →
VCEL
Vericel Corporation
D+ 58/100 133.0x 74.4% 3.4% +0.62% $2.06B /vcel-vs-meso →
ALVO
Alvotech
D+ 52/100 — — — -3.66% $1.82B /alvo-vs-meso →

2. MESO Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Mesoblast Limited (MESO) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $1.97B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. MESO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MESO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Mesoblast Limited (NASDAQ: MESO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $14.54 (-4.09% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MESO ranks #252 in composite RQD confidence.

How does MESO compare to COAG and VIR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MESO carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, COAG (Hemab Therapeutics Holdings Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $1.94B) and VIR (Vir Biotechnology Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $1.93B). Among the 5-stock peer group, VCEL leads on earnings multiple (133.0x) while VCEL leads on capital efficiency (3.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MESO?

For Mesoblast Limited (MESO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #252 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MESO trading relative to its 50-day, 200-day, and 52-week technical levels?

MESO last traded at $14.54 (-4.09% on volume of 261,321 shares), positioning the stock -2.22% below its 50-day simple moving average ($14.87) and -5.52% below its 200-day simple moving average ($15.39). Across its 52-week range of $11.89 to $21.50, MESO sits at the 27.6% percentile with a 14-day RSI of 57.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.5% ($13.30 to $15.78).

Direct Sub-Reports: MESO RQD Cockpit MESO 12M Forecast MESO Earnings & Move MESO Dividends & DRIP MESO Insiders & 13F MESO Whale Options MESO Profit Sankey MESO News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ SEC XBRL & RQD VERIFIED

MESO — Mesoblast Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Mesoblast Limited (MESO) earns a live Roarable RQD composite score of 51/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $14.54 (-4.09% 1D, market capitalization $1.97B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Mesoblast Limited (MESO) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..0B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 51/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $11.89 – $21.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or 2nd-order bottlenecks are identified in the source data.

  • Key Question #1: Can MESO sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $21.50 52-week high?
  • Key Question #3: How sensitive is MESO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MESO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Mesoblast Limited (MESO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MESO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MESO Bull vs. Bear Conversation Board — What's Your Call at $14.54?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MESO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MESO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $18.19 (+20.0%)
📌 Pinned Debate

The Forensic Balance Sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and the news-wire reference to a 44% fiscal Q

Long MESO at $15.16 targeting $18.19. The Forensic Balance Sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and the news-wire reference to a 44% fiscal Q1 net revenue increase provide the strongest positive datapoints.. Institutional whale score is 9/20 and the risk/reward vs. the $11.89 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $12.28 (-19.0%)
Spot @ $15.16

ROIC 0%, FCF yield 0%, and an RQD verdict of Roarable Sell — Weak Fundamentals / Trim leave the price move of 17.03% unsupported by rep

Here is the bear case nobody on the bull side wants to address on MESO: ROIC 0%, FCF yield 0%, and an RQD verdict of Roarable Sell — Weak Fundamentals / Trim leave the price move of 17.03% unsupported by reported profitability or cash generation.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%